REZOLUTE, INC. Basic Shares Outstanding (Weighted Average)
REZOLUTE, INC. (RZLT) reported Basic Shares Outstanding (Weighted Average) of 103.91 million shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-09-24
- REZOLUTE, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 104.49M shares, a 10.81% increase year-over-year.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 104.04M shares, a 48.56% increase year-over-year.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 103.69M shares, a 48.25% increase year-over-year.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 103.42M shares, a 48.31% increase year-over-year.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for fiscal 2026 was 103.91M shares, a 36.72% increase from fiscal 2025.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 76.00M shares, a 47.67% increase from fiscal 2024.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 51.47M shares, a 0.55% increase from fiscal 2023.
- REZOLUTE, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 51.19M shares, a 181.29% increase from fiscal 2022.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 104.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 104.26M shares derived: average of 2 quarters · filed 2026-09-24 | 104.07M shares derived: average of 3 quarters · filed 2026-09-24 | 103.91M shares 10-K · filed 2026-09-24 | ||||
| 2026-03-31 | 104.04M shares 10-Q · filed 2026-05-12 | 103.86M shares derived: average of 2 quarters · filed 2026-05-12 | 103.71M shares 10-Q · filed 2026-05-12 | 101.36M shares derived: average of 4 quarters · filed 2026-09-24 | ||||
| 2025-12-31 | 103.69M shares 10-Q · filed 2026-02-12 | 103.55M shares 10-Q · filed 2026-02-12 | 100.47M shares derived: average of 3 quarters · filed 2026-09-24 | 92.86M shares derived: average of 4 quarters · filed 2026-09-24 | ||||
| 2025-09-30 | 103.42M shares 10-Q · filed 2025-11-06 | 98.86M shares derived: average of 2 quarters · filed 2026-09-24 | 89.25M shares derived: average of 3 quarters · filed 2026-09-24 | 84.42M shares derived: average of 4 quarters · filed 2026-09-24 | ||||
| 2025-06-30 | 94.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 82.16M shares derived: average of 2 quarters · filed 2026-09-24 | 78.09M shares derived: average of 3 quarters · filed 2026-09-24 | 76.00M shares 10-K · filed 2026-09-24 | ||||
| 2025-03-31 | 70.03M shares 10-Q · filed 2026-05-12 | 69.99M shares derived: average of 2 quarters · filed 2026-05-12 | 69.90M shares 10-Q · filed 2026-05-12 | 65.48M shares derived: average of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | 69.94M shares 10-Q · filed 2026-02-12 | 69.94M shares 10-Q · filed 2025-02-12 | 69.84M shares 10-Q · filed 2026-02-12 | 69.84M shares 10-Q · filed 2025-02-12 | 63.97M shares derived: average of 3 quarters · filed 2026-02-12 | 60.68M shares derived: average of 4 quarters · filed 2026-02-12 | ||
| 2024-09-30 | 69.74M shares 10-Q · filed 2025-11-06 | 69.74M shares 10-Q · filed 2024-11-07 | 60.98M shares derived: average of 2 quarters · filed 2025-11-06 | 57.59M shares derived: average of 3 quarters · filed 2025-11-06 | 56.05M shares derived: average of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | 52.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | 51.52M shares derived: average of 2 quarters · filed 2025-09-17 | 51.48M shares derived: average of 3 quarters · filed 2025-09-17 | 51.47M shares 10-K · filed 2025-09-17 | 51.47M shares 10-K · filed 2024-09-19 | |||
| 2024-03-31 | 50.81M shares 10-Q · filed 2025-05-13 | 50.81M shares 10-Q · filed 2024-05-15 | 51.11M shares derived: average of 2 quarters · filed 2025-05-13 | 51.21M shares 10-Q · filed 2025-05-13 | 51.21M shares 10-Q · filed 2024-05-15 | 51.26M shares derived: average of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | 51.41M shares 10-Q · filed 2025-02-12 | 51.41M shares 10-Q · filed 2025-02-12 | 51.41M shares derived: average of 3 quarters · filed 2025-02-12 | 51.41M shares derived: average of 4 quarters · filed 2025-02-12 | ||||
| 2023-09-30 | 51.41M shares 10-Q · filed 2024-11-07 | 51.41M shares derived: average of 2 quarters · filed 2024-11-07 | 51.41M shares derived: average of 3 quarters · filed 2024-11-07 | 51.41M shares derived: average of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | 51.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | 51.41M shares derived: average of 2 quarters · filed 2024-09-19 | 51.41M shares derived: average of 3 quarters · filed 2024-09-19 | 51.19M shares 10-K · filed 2024-09-19 | ||||
| 2023-03-31 | 51.41M shares 10-Q · filed 2024-05-15 | 51.41M shares derived: average of 2 quarters · filed 2024-05-15 | 51.11M shares 10-Q · filed 2024-05-15 | 46.22M shares derived: average of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | 51.41M shares 10-Q · filed 2024-02-13 | 50.97M shares 10-Q · filed 2024-02-13 | 44.49M shares derived: average of 3 quarters · filed 2024-02-13 | 37.67M shares derived: average of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | 50.53M shares 10-Q · filed 2023-11-13 | 41.04M shares derived: average of 2 quarters · filed 2023-11-13 | 33.10M shares derived: average of 3 quarters · filed 2023-11-13 | 28.74M shares derived: average of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | 31.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-14 | 24.38M shares derived: average of 2 quarters · filed 2023-09-14 | 21.48M shares derived: average of 3 quarters · filed 2023-09-14 | 18.20M shares 10-K · filed 2023-09-14 | ||||
| 2022-03-31 | 17.22M shares 10-Q · filed 2023-05-11 | 16.45M shares derived: average of 2 quarters · filed 2023-05-11 | 13.75M shares 10-Q · filed 2023-05-11 | 12.44M shares derived: average of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | 15.68M shares 10-Q · filed 2023-02-10 | 12.10M shares 10-Q · filed 2023-02-10 | 10.85M shares derived: average of 3 quarters · filed 2023-02-10 | 10.22M shares derived: average of 4 quarters · filed 2023-02-10 | ||||
| 2021-09-30 | 8.51M shares 10-Q · filed 2022-11-09 | 8.43M shares derived: average of 2 quarters · filed 2022-11-09 | 8.40M shares derived: average of 3 quarters · filed 2022-11-09 | 8.31M shares derived: average of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | 8.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-15 | 8.35M shares derived: average of 2 quarters · filed 2022-09-15 | 8.25M shares derived: average of 3 quarters · filed 2022-09-15 | 7.67M shares 10-K · filed 2022-09-15 | ||||
| 2021-03-31 | 8.35M shares 10-Q · filed 2022-05-12 | 8.20M shares derived: average of 2 quarters · filed 2022-05-12 | 7.45M shares 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | 8.04M shares 10-Q · filed 2022-02-09 | 6.96M shares 10-Q · filed 2022-02-09 | ||||||
| 2020-09-30 | 5.87M shares 10-Q · filed 2021-11-12 | |||||||
| 2014-06-30 | 9.38M shares 10-K · filed 2014-09-30 | |||||||
| 2013-06-30 | 6.20M shares 10-K · filed 2014-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |